2486 Dunwin Drive
133 articles with Acerus Pharma
8/8/2019Biopharma companies from across the globe share business and development updates.
Strengthened balance sheet with US$5 million subordinated secured loan facility in July
NATESTO® Spermatogenesis Study Final Results Accepted for Presentation at the American Society for Reproductive Medicine 75th Annual Scientific Conference
Final study results accepted for “Late Breaking Presentation” on October 16, 2019
Acerus Pharmaceuticals Corporation announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc.
Acerus Pharmaceuticals Corporation will announce its second quarter 2019 financial and operating results on Wednesday, August 7, 2019 before the market opens.
Acerus Congratulates US Partner Aytu Bioscience on Listing of NATESTO® on National Pharmacy Benefit Manager’s Formulary
Acerus Pharmaceuticals Corporation announced that NATESTO® is now on formulary and covered nationwide by a leading national pharmacy benefit manager in the United States.
Acerus Pharmaceuticals Corporation announced that it has entered into a US$5 million subordinated secured term loan facility with First Generation Capital Inc., a company affiliated with the Chairman of the Board of Directors of Acerus.
Acerus Pharmaceuticals Corporation announced an update relative to the Company’s NATESTO® business.
Acerus Announces Publication of Study Results Demonstrating Effectiveness of NATESTO® Regardless of Baseline Symptom Severity
Acerus Pharmaceuticals Corporation announced the acceptance of a new manuscript to the Journal of the Endocrine Society, describing how NATESTO® achieves similar symptom improvement, regardless of the degree of a patient’s baseline testosterone deficiency.
Acerus Pharmaceuticals Corporation announced that Health Canada has completed the initial screening process for the previously announced New Drug Submission for avanafil.
Acerus Reaches Mutual Agreement with Innovus Pharma to Terminate Distribution and License Agreement for UriVarx® in Canada
Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF.
Acerus Pharmaceuticals Corporation announced that it has signed a patent license agreement with the University of Texas at Austin for technology related to the nasal administration of testosterone.
Acerus Pharmaceuticals Corporation reported its financial results for the three-month period ended March 31, 2019.
Acerus Pharmaceuticals Corporation will announce its first quarter 2019 financial and operating results on Monday May 13, 2019 before the market opens.
Acerus Pharmaceuticals Corporation announced that it has engaged Paradigm Capital Inc. as its financial advisor to leverage its proprietary nasal delivery technology in cannabinoid applications through licensing, partnership agreements or other transactions with interested parties.
Acerus Pharmaceuticals Corporation announced that Edward Gudaitis, President and Chief Executive Officer of Acerus, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference.
Acerus Pharmaceuticals Corporation reported its financial results for the three and twelve-month period ended December 31, 2018.
Acerus Pharmaceuticals Corporation announced that it has filed a New Drug Submission for Avanafil with Health Canada.
Acerus Pharmaceuticals Corporation announced two updates relative to the Company’s NATESTO® business.
Acerus Pharmaceuticals Corporation will announce financial results for the three and twelve month periods ending December 31, 2018 on Tuesday, March 05, 2019 before market opens.